Robotic Lab Assistant

Our leadership team brings together some of the best minds in age-related science and investment strategy.

With decades of experience in the space, our diverse team possesses a deep collective understanding of geroscience therapeutics. We are driven by collaboration and are committed to cultivating company-wide opportunities to learn and grow together.

Electronic Chip



CEO & Co-Founder

James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Biopharma. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. He led investments in Cleara Biotech, Aeovian Pharmaceuticals, and Samsara Therapeutics, and served on the Board and/or in executive roles for all three companies. James has led companies that have raised over $100M. He serves on the board of Sensei Biotherapeutics, Vineyard Therapeutics, and several more stealth-mode companies. Prior to Apollo, James was a consultant at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.

Chairman & Co-Founder

Christian Angermayer is a Chairman and Co-Founder of Cambrian Biopharma. A serial entrepreneur and investor, Christian has raised over $1.6B for his portfolio companies. He was co-founder of Ribopharma, a German biotech company pioneering RNAi (today Alnylam, $9B market cap). Via his family office Apeiron Investment Group, he has invested in many companies in the life sciences and fintech sectors and has been party to over 40 successful M&As and IPOs. He is a founder and investor in another biotech holding company, ATAI Life Sciences, focused on neuropharmacology. In 2017, the Swiss-German business magazine BILANZ ranked Christian in the top 10 most important German tech investors. Christian has produced 14 feature films and was named an emerging global leader by the World Economic Forum and the Milken Institute.

Chief Operating Officer

Juliette Han is the Chief Operating Officer at Cambrian Biopharma. She was previously the Chief of Staff at Two Sigma Private Investments Group, the PE/VC division of the hedge fund Two Sigma. Prior to Two Sigma, Juliette was a Chief Operating Officer of People & Human Resources Operations at the hedge fund Citadel, where she transformed the zero data transparency organization to a live-dashboard and quant-driven culture. Prior to Citadel, Juliette was Chief of Staff for McKinsey New Ventures at McKinsey & Co in the New York office. Juliette holds a Ph.D. in Neuroscience from Harvard University, as well as an M.S. in Physiological Sciences and B.S. in Neuroscience and Physiological Science, both from the University of California Los Angeles (UCLA). She serves on the alumni advisory council of Harvard Medical School.

EVP, Translational & Clinical Science

Tauhid Ali is the Executive Vice President of Translational & Clinical Science at Cambrian Biopharma. He was previously at Takeda Pharmaceuticals as VP of Search & Translational Science (Rare Diseases Therapy Area Unit) and the founder and head of the TAKceleratorā„¢, a virtual biotech unit within Takeda with a novel operating model, which, within the first two years, launched 3 new companies with venture backing and executed multiple out licenses and partnerships, achieving a healthy ROI. Prior to Takeda, he was Global Project Leader for Early Development at UCB Celltech focused on small molecules and mAb development where he led global development project teams in immunology & inflammation including a co-development with Biogen-Idec in a rare auto-inflammatory program. He has a Ph.D. from Cardiff University and a MSc in Clinical Sciences from the Welsh School of Pharmacy.

EVP, Chemistry

Dennis Yamashita is a highly experienced and accomplished drug hunter and medicinal chemist with extensive leadership experienced as GSK and in biotech. He is co-inventor of five clinical candidates including oliceridine (OLINVO), Trevena's Mu opioid G-protein biased ligand, that has received FDA breakthrough status and completed Phase 3 clinical trials for post-operative pain. Prior to joining Cambrian, Dr. Yamashita served as Vice President of Medicinal Chemistry at Axial Biotherapeutics, a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. He has also held various leadership roles as GSK, ORIC, and Trevena. Dr. Yamashita holds a BSc. in Chemistry from MIT and a Ph.D. in Organic Chemistry from Yale University. His Ph.D. thesis was conducted in the labs of Prof. Samuel J. Danishefsky on the synthesis of the bicyclic enediyne natural product, calicheamicinone. 

EVP, Drug Discovery

Georg Terstappen is the Executive Vice President of Drug Discovery at Cambrian Biopharma. Georg has over 25 years of experience in big pharma and biotech, holding senior R&D positions at Bayer, GW/GSK, and Abbott/AbbVie - most recently as Head of Preclinical CNS Drug Development with GSK in Shanghai. Georg was also co-founder and CSO of the CNS drug discovery company Siena Biotech and CSO of OxStem (a University of Oxford spin-out focused on regenerative medicine). In addition, Georg has led EU R&D framework organizations as Vice-Chair of the Innovative Medicines Strategy group in the context of EFPIA and IMI. He has over 80 publications and 15 patents. Georg has a first-class honors degree in Biology and conducted research at the Max Planck Institute in Cologne and the Federal Research Centre Juelich for which he has received a PhD in natural sciences.

Board of Directors

Board Observer




Venture Director

Venture Director

Venture Director

Scientist in Residence

Vice President, Ventures 

Venture Director

Pipeline Operations

Director of Operations

Director of Operations

Director of Operations

Office of the CEO

Chief of Staff 

Associate, Office of the CEO

  • LinkedIn